Epidarex Capital funds the commercialization of ground-breaking research and new technologies to address large and unmet needs in today’s healthcare market.
Epidarex’s therapeutic discovery engine will identify innovative early stage assets, providing hands-on scientific support and funding to drive drug discovery projects Exeed will mould and de-risk o... 18 month project in collaboration with University of Leeds and Medicines Discovery Catapult will deliver a new compound for treatment of thrombosis Currently available anticoagulants carry high risk o...
Epidarex Exeed Founded by Epidarex Capital to Advance Early Stage, Highly Innovative Life Science Assets
LUNAC Therapeutics Led Project Awarded £3.14 million Under Innovate UK Biomedical Catalyst Programme, to Develop Next-Generation Anticoagulant